MindBio Therapeutics Corp
CNSX:MBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MindBio Therapeutics Corp
Other Non-Cash Items
MindBio Therapeutics Corp
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MindBio Therapeutics Corp
CNSX:MBIO
|
Other Non-Cash Items
AU$1.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Non-Cash Items
$211m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Other Non-Cash Items
$63.1m
|
CAGR 3-Years
34%
|
CAGR 5-Years
58%
|
CAGR 10-Years
20%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Non-Cash Items
CA$19.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Other Non-Cash Items
CA$38.1m
|
CAGR 3-Years
361%
|
CAGR 5-Years
104%
|
CAGR 10-Years
62%
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Other Non-Cash Items
$116k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-34%
|
|
MindBio Therapeutics Corp
Glance View
Mindbio Therapeutics Corp. engages in developing psychedelic medicines to treat medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-05-05. The firm is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. The company has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. The company has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The firm invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
See Also
What is MindBio Therapeutics Corp's Other Non-Cash Items?
Other Non-Cash Items
1.7m
AUD
Based on the financial report for Jun 30, 2025, MindBio Therapeutics Corp's Other Non-Cash Items amounts to 1.7m AUD.
What is MindBio Therapeutics Corp's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
-4%
Over the last year, the Other Non-Cash Items growth was 773%. The average annual Other Non-Cash Items growth rates for MindBio Therapeutics Corp have been -4% over the past three years .
